Today reinforces why $W Wayfair shareholders should be concerned. Multi-channel – Valuation – Supply Chain

, ,

Citron Reiterates Wayfair Short Term $50 Target

Grocery stocks are getting hit hard today on the fear of Amazon disrupting their supply chains.  Similarly, as Amazon enters furniture, it breaks Wayfair’s strategic hold on it supply chain.  (MAJOR STATED RISK FACTOR IN WAYFAIR FILINGS)

 

  1. The Gorilla Enters the Room. The market reactions we see today in Kroger, Target, and WalMart (all profitable) show the fear in the market for businesses vulnerable to competition from Amazon.

 

  1. The importance of multi-channel retailing. $AMZN proves that some
    e-commerce solutions absolutely require local physical presence: Groceries are one, and furniture is the other.  Case-in-point: Amazon’s new “Unified Delivery with Services” program for furniture.

 

  1. Real companies get real valuations: $WFM got bought for 10.7 times next 12 months EBIDTA.  $W is a throwback to 1999, a business where there’s never EBIDTA, just cumulative losses.

  1. Profits? Never ever.  If Wayfair couldn’t make money before Amazon was a competitor, how can they possibly ever become profitable with Amazon pushing hard into their only marketplace?

 

  1. Forget Bailout by Walmart. Do not forget WalMart’s new national ad campaign rollout for Hayneedle – don’t expect any bailout for Wayfair from Bentonville.

 

  1. “Amazon Who?” Whenever an online retailer’s CEO says on a conference call he is “not concerned about Amazon” — and dismisses them saying they sell “batteries and books” … it is time to be concerned about your CEO.

 

  1. Follow the Money: Insider selling last 6 months for Whole Foods = $2 million, for Wayfair last 6 weeks $220 million.

 

  1. Analyst Shmanalyst. The analysts are so lost that the last upgrade on Wayfair (Piper) did not even have the word “Amazon” in the report.  Analyzing an e-commerce company without acknowledging Amazon is like writing about the 2017 NBA season and refusing to mention the  G.S. Warriors.

 

Cautious Investing to All.

Could Blackberry be the Next NVIDIA?

,

Citron learns from history that we could be in the first stages of a “WOW” move from Blackberry

BlackBerry 24 month target:  $20. or  Likely Buyout Target at a Sizeable Premium

Blackberry as the next NVIDIA

An interesting point not known by most NVDA shareholders, and definitely not talked about on CNBC — While the enterprise value of NVDA stock has gone from $5 billion to $85 billion over the past 2 years…its revenues have only doubled.

Why? Because Wall Street stopped valuing NVDA as a graphic chip company and instead looked at its future in autonomous driving, AI, and datacenter tech. It wasn’t revenue growth that drove the stock, but rather what segment the growth was coming from.

So before you buy NVDA at $140, check out $BBRY.

Read the rest of the report here.

 

 

 

IF YOU DON’T BELIEVE CITRON BELIEVE THE SCIENCE

,

To Reveal the True Value of Exact Sciences (NASDAQ:EXAS) Listen to the Highly Respected Company that is the ”Science” behind Exact Sciences

Short Term Target Reaffirmed at $20 … Long Term Looks Dire

 

Citron is surprised that neither investors nor analysts properly analyzed the important disclosure from Exact on April 27th.   Citron notes that the company did not issue a PR for this transaction, but suggests that all investors seeking insight into the company’s prospects had better consider it carefully.

For the story you won’t read anywhere else, Click Here … 

Citron Research exposes Exact Sciences and PROVES beyond ANY doubt why this stock will soon be cut in half

, , ,

Every Man and Woman Over The Age of 50 MUST read this report from Citron Research

Short term target:  $20.

3 to 5 Years:  Likely Single Digit, Potential 0.

Exact Sciences (NASDAQ:EXAS) pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it.  That is why this $4 billion company is mainly owned by passive investing ETFs or other healthcare baskets.

More importantly, as Citron will expose, the key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.

This stock is a poster child for what goes wrong when Wall Street gets ahold of a health care concept with no discrimination for whether its good or bad medicine.

For the rest of the story you won’t read anywhere else, click here: 

 

Citron Exposes the Dirty Illegal Secrets of FleetCor, and Proof the Company is Already in Cover-Up Mode

, ,

Short Term Price Target = $80

In our first report Citron referred to FleetCor (NYSE:FLT) as “FeeCor” and “FleeceCor”.  The bulls defended the company, claiming FleetCor’s customer fees are legal, not egregious, and most of all are sustainable.

In this report Citron clarifies the illegality of FleetCor’s corporate practices, and the lengths the analyst community goes to in defending them.

For the rest of the story you won’t read anywhere else, Click Here…